MONTROUGE, France, March 1, 2016 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that multiple members of its management team will present and host investor meetings at the following events in March, 2016:
- Susanna Mesa, Vice President of Finance, Investor Relations & Strategy, will present at the LEERINK Partners Annual Emerging Biotech Conference in Snowbird, UT, on Wednesday, March 9, 2016, at 4:00 pm UTC.
- Charles Ruban, Chief Commercial Officer, and Susanna Mesa, Vice President of Finance, Investor Relations & Strategy, will present at the Barclays Global Healthcare Conference in Miami, FL, on Wednesday, March 16, 2016, at 2:35 pm ET.
- David Schilansky, Chief Operating Officer, and Susanna Mesa, Vice President of Finance, Investor Relations & Strategy, will host investor meetings during the Morgan Stanley Healthcare Corporate Access Day in Boston, MA, on Wednesday, March 23, 2016.
- Pierre-Henri Benhamou, Chairman and Chief Executive Officer, and David Schilansky, Chief Operating Officer, will host investor meetings during the Exane BNP Paribas Healthcare Conference in Paris (France), on Wednesday, March 16, 2016.
Live audio webcasts of the Barclays Conference will be available on the Investor Relations section of the Company's website: http://www.dbv-technologies.com/en/investor-relations. A replay of the presentation will also be available on DBV's website within 48 hours after the event.
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
|DBV Technologies Contacts|
|Nathalie Donne Director, Corporate Communication & Business Development Tel. : +33 (0)1 55 42 78 72 email@example.com||Susanna Mesa VP of Finance, Investor Relations & Strategy Tel. : +1 212-271-0861 firstname.lastname@example.org|
|DBV Technologies Media Contacts US & Europe|
|Marion Janic Rooney & Associates Tel. : +1 212-223-4017 email@example.com|| Caroline Carmagnol |
Alize RP - Relation Presse
Tel. : +33 (0)6 64 18 99 59
PDF Version http://hugin.info/156437/R/1990572/731369.pdf